Table III.

Effect of topical treatment with heparin activated antithrombin III (hep-ATIII) on the mortality of SKH-1 mice infected orofacially with HSV-1

	Mortality
Treatmenta	Number	Percent	P-value	MDD ± STDb	P-value
Vehicle
Carbopol gel	9/10	90	---	7.4 ± 1.7	---
Zovirax
5% ACV	0/10	0	<0.001	---	---
Hep-ATIII
10 mg/ml	4/10	40	<0.01	7.5 ± 0.6	NSc

^a.Topical treatments with vehicle, ACV, and hep-ATIII were applied topically 3 times daily for 7 consecutive days in 6 hour intervals beginning 24 hours post viral inoculation.

^b.MDD = Mean Day of Death. STD = Standard Deviation.

^c.NS = Not significant when compared to the appropriate vehicle control.